Investing With IBD

Ep. 133: Nina Deka: Healthcare Technology Still In Early Stages Of Disruption

10.07.2021 - By Investor's Business DailyPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

Nina Deka, Senior Research Analyst at ROBO Global, points out some huge problems in the healthcare industry that are ripe for innovative solutions. After looking at some of five major themes, Nina revisits some stocks from her last appearance like 1Life Healthcare (ONEM) and Teladoc (TDOC) as well as the stories behind Tabula Rasa (TRHC) Akoya BioSciences (AKYA), Catalent (CTLT), Dexcom (DXCM) and Fate Therapeutics (FATE). For the video version, show notes and charts, visit investors.com/podcast.

Learn more about your ad choices. Visit megaphone.fm/adchoices

More episodes from Investing With IBD